# MAPKeeper 301 (NCT07562152)

> Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07562152
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Immuneering Corporation
- Conditions: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma
- Interventions: Atebimetinib; GnP; mGnP
- Enrollment: 510
- Primary outcome: Overall Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 2
- Podcasts: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mapkeeper-301-nct07562152